Streamlined flu testing with ARIES® Systems
Flu season is rapidly approaching. As usual, experts at the U.S. Centers for Disease Control and Prevention recommend getting a flu vaccine by the end of October — but now, they’re calling for only flu shots. Nasal spray vaccines are no longer recommended. This year’s vaccine protects against a cocktail of influenza A and B viruses (see details from the CDC).
While flu season keeps parents on the lookout for runny noses, it has a more immediate impact on clinical lab teams, which will begin more frequent testing for flu strains in the coming months. We’re pleased to report that labs using our ARIES® Systems will now be able to take advantage of the FDA-cleared ARIES® Flu A/B & RSV Assay. In less than two hours, the assay can accurately distinguish between influenza A virus, influenza B virus, and respiratory syncytial virus from nasopharyngeal swab specimens.
The ARIES® Flu A/B & RSV Assay offers:
- High sensitivity: High clinical performance reduces the need for confirmatory testing and time to treatment.
- High accuracy: Confidence in results gives patients and clinicians peace of mind and helps ensure correct treatment.
- Fast time to results: Answers in as few as two hours will allow physicians to counsel patients and treat sooner and possibly decrease disease transmission.
- Full integration: Automate all aspects of testing, from sample preparation through analysis, to reduce human error.
Disclaimer: The test is intended for use as an aid in the differential diagnosis of Influenza A, Influenza B, and RSV in humans and is not intended to detect Influenza C. Negative results do not preclude influenza virus or RSV infection and should not be used as the sole basis for diagnosis, treatment or other management decisions. Conversely, positive results do not rule-out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. The use of additional laboratory testing (e.g., bacterial culture, immunofluorescence, X-ray findings) and clinical presentation must be taken into consideration in order to obtain the final diagnosis of respiratory viral infection.
For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at support@luminexcorp.com to obtain the appropriate product information for your country of residence.